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Receptors  on  lymphocytes  play a  crucial  role  in antigen  recognition  and  effector 
function  during an immune response.  In the case of the B  cell, this antigen  receptor 
has  been  conclusively  identified  as  immunoglobulin  (1,  2).  In  contrast,  despite 
intensive  investigation,  the exact  identity  of the T  cell  receptor  for antigen  remains 
unknown.  Some  studies  using  conventional  anti-idiotypic  antisera  have  suggested 
similarities  between  T  cell  receptors  and  the  VH region  of immunoglobulin  (3,  4), 
whereas  other  experiments  involving  anti-isotypic  antisera  indicate  the  presence  of 
to- (5, 6) and ~-like (7, 8) molecules on the surface ofT lymphocytes. However, because 
all  such  studies  suffer from the  difficulties  associated with  the  use of poorly defined 
conventional  antisera,  the relationship  between classical immunoglobulin  and  the T 
cell receptor remains a  subject of great controversy. 
Previous  studies  on  the  T  cell  receptor  have  used  anti-idiotypic  or  anti-isotypic 
antiserum prepared against purified immunoglobulin, and subsequently tested against 
T  cells. To allow for a more precise characterization  of immunoglobulin-cross-reactive 
molecules on T  cells, we chose an alternative  approach:  first to prepare monoclonal 
antibodies against T  cells, and then to test these for binding to purified immunoglob- 
ulin.  In this report, we describe the isolation of one such monoclonal antibody, 42-21, 
which detects an antigenic  determinant  shared by the V~ light chain of the TEPC 15 
(T15) 1 myeloma protein and the Thy-1  antigen  on all T  cells. 
Materials  and  Methods 
Antibodies.  42-21  is  a  rat  IgM  hybridoma  prepared  by  immunization  against  the  AKR 
spontaneous T  lymphoma KKT-2. 31-11  is a rat IgG~ monoclonal antibody specific for the 
constant portion of mouse Thy-1. The preparation of these two antibodies has been described 
elsewhere (9). 71-11 is a rat monoclonal prepared against the purified T15 myeloma protein. It 
recognizes a cross-reactive idiotypic determinant present on all phosphorylcholine ( PC)-binding 
myelomas (E.  Pillemer and I. Weissman, manuscript  in preparation).  Monoclonal anti-Lyt-1 
(subcione 53-7.313)- and anti-Lyt-2 (subclone 53-6.72)-producing hybridoma cell lines were a 
generous gift ofJ. Ledbetter, Stanford University (I0). 
* Supported  by grant  AI-09072 from the U. S. Public  Health Service, and grant IM-561 from the 
American Ccancer Society. 
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1  Abbreviations used in this paper: BSA, bovine serum albumin;  FA(]S, fluorescence-activated cell sorter; 
F(]S,  fetal  calf serum;  FIT(I,  fluorescein  isothiocyanate;  MEM,  minimum  essential  medium;  PBS, 
phosphate-buffered saline; PC, phosphorylcholine; T 15, TEP(] 15. 
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Myeloma Proteins, Recombined Molecules, Hybridoma Immunoglobulins, and Isolated Heavy and Light 
Chains.  Column-purified myeloma proteins were  a  generous  gift  of R.  Coffman  and  C. 
Nottenburg, Stanford University. The hybridoma anti-PC antibodies M2, M3, and G1 were 
provided by P. Gearhart, Carnegie Institution of Washington; the chain composition of these 
antibodies has been determined by amino acid sequence analysis (11). All three hybridomas 
possess the T15 H chain; M2 has the T15 L chain, M3 has the MePC603 L chain, and G1 has 
the  MOPC167  L  chain.  Hybridoma anti-PC antibodies representing the  two  kappa chain 
markers were a gift of L. Claflin, University of Michigan (12). The three hybridomas are all of 
the IgM isotype; 221A4 is from an AKR animal (I~ac-Pca), 991G2 is from a C58 animal (Ig~c- 
Pc  a)  and 552D3 is from a  BALB/c animal (Iglc-Pe~). The isolated heavy and light chains of 
TI5 and W3207 and the McPC603 H/T15 L  recombined molecules were obtained from A. 
Goetze, California Institute of Technology (13).  BALB/c immunoglobulin was prepared by 
50% ammonium sulfate precipitation from normal serum. 
Cell Lines.  All cell lines are maintained in culture in our laboratory in RPMI-1640 medium 
supplemented with 10% fetal calf serum (FCS). The T  lymphomas used in this study include: 
the spontaneous AKR lymphoma KKT-2, the RadLV-induced C57BL/Ka lymphoma VL-3 
(obtained from H. Kaplan, Stanford University), the chemical-induced C57BL/6 tumor EL4, 
and  the radiation-induced C57/L  lymphoma L691.  The non-T tumors used  in this study 
include: the DBA/2 mastocytoma P815,  the BALB/c nonprodueer myeloma NS-1, and the 
Abelson virus-induced pre-B cell tumors L1-2 and RAW112, of C57L and BALB/e origin, 
respectively. The  BW5147 parental line (Thy-1 +)  and the Thy-1- mutants, B5147.6.1  and 
BW5147.3,  were obtained from R. Hyman at The Salk Institute, San Diego, Calif. (14). 
Synthetic Labeling of Monoclonal Antibodies.  Hybridoma cell  lines were obtained from tissue 
culture and washed  twice  in Hanks' balanced salt solution without serum. The cells  were 
resuspended in leucine-free minimum essential medium (MEM) plus 5% dialyzed FCS (MEM- 
6  3  3  5) and adjusted to 3 ×  10/ml. 5/~Ci/ml of [ H]leueine was added together with 0.01 ml of 10- 
M cold leueine to give a final leucine concentration of 10  -5 M. 3 ml of cell solution was plated 
in petri dishes at 37°C plus 7% CO2. After 5 h incubation, 0.09 ml of complete MEM-5 was 
added to each plate. After an additional 30 rain, the cell suspension was spun for 6 min at 1,200 
rpm to  pellet the cells.  The supernatant was  dialyzed three times against  100×  volume of 
phosphate-buffered saline plus 1 mM sodium azide (PBS-Az),  and then clarified by spinning 
for 10 min at  10,000 rpm. 
Myeloma-binding Assays.  Solid-phase immunoassays were performed in 96-well  flexible mi- 
crotiter plates  (Dynatech Laboratories, Inc., Dynatech Corp.,  Alexandria, Va.).  Wells were 
coated for 16 h at 4°C with 0.05 ml of a 100/Lg/ml solution of the myeloma ~rotein in PBS-Az. 
After washing three times with PBS-Az plus 5% FCS (PBS-5),  0.05 ml of [ H]leueine-labeled 
hybridoma supernate (25,000-50,000 cpm) was added to each well. After incubation for 2 h at 
4°C, the wells were again washed three times with PBS-5,  cut using a  hot wire device, and 
transferred to scintillation  fluid (Biofluor; New England Nuclear, Boston, Mass.)  for counting. 
Cell-binding Assay.  Assays were performed in 96-well microtiter plates. Cell suspensions were 
prepared in cell suspension medium plus 5% FCS (CSM-5) and adjusted to 2.5 ×  l0  T  cells/ml. 
2.5  ×  105  cells  were  added  to  each  well  together with 0.04  ml of 3H-labeled monoclonal 
antibody (25,000-50,000 cpm). After incubation at 4°C for 1 h, the wells were washed three 
times with PBS-5. The wells were cut using a hot wire and transferred to scintillation fluid for 
counting. In some assays, unlabeled hybridoma supernatant fluids were used as the first stage 
rather than the ~H-labeled antibody. In this case, a second-stage ~28I rabbit anti-rat Ig (25,000- 
50,000  cpm in 0.025  ml) was added to the cells  and incubated for  1 h  at  4°C. After three 
washes  in PBS-5,  the wells  were  cut  with  a  hot  wire and transferred directly to  tubes for 
counting. 
Fluorescence-activated  Cell Sorter (FACS) Analysis.  Cell suspensions of normal lymphoid tissues 
or tissue culture lines were prepared in CSM-5 at a concentration of 10a/ml. 0.01  ml of cells 
was added to a conical tube together with 0.04 ml of hybridoma antibody. After incubation for 
15 min on ice, the ceils were washed once over an FCS underlayer. The pellet was re.suspended 
in 0.01  ml of fluorescein isothioeyanate (FITC)-labeled rabbit anti-rat Ig second stage and 
incubated for 15 min on ice. After a final wash over FCS, the cells were resuspended in 1 ml of 
PBS-Az for FACS analysis. 1070  A V,-TEPC15  IDIOTYPE CROSS-REACTIVE WITH Thy-1 
Inhibition of Antibody Binding to T15.  0.05 ml ofT15  (100 #g/ml) was added to each well of 
a microtiter plate and incubated for 16 h at 4°C, and the wells were washed three times with 
PBS-5. For hapten inhibition of 42-21  binding, a PC-bovine serum albumin (BSA) conjugate 
was  prepared  using p-diazonium  phenylphosphorylcholine  (Biosearch,  San  Rafael,  Calif.) 
according to the method of Cosenza et al (15). Various dilutions of PC-BSA were added to the 
T15-coated  wells and  incubated  for  an  additional hour.  For antibody  inhibition of 42-21 
binding, 0.05  ml of unlabeled hybridoma supernate was added to each well. In either case, 
after 1 h  at 4°C, the wells were washed three times with PBS-5, and 0.025 ml of 3H-labeled 
antibody (25,000-50,000 cpm) was added. After an additional 1 h incubation, the plates were 
again washed, and the wells were cut with a hot wire and transferred to scintillation vials for 
counting. 
Inhibition of Myeloma Binding to 42-21.  In some cases, microtiter plates were coated for 16 h 
at 4°C with 0.05 ml of purified rabbit anti-rat Ig serum (100 #g/ml) in PBS-Az. The wells were 
washed  three  times  with  PBS-5,  and  0.05  ml  of hybridoma  supernate  was  added.  After 
incubation for  1 h  at  4°C,  the wells were washed and  then  incubated with 0.05  ml of 1% 
normal  mouse  serum  to  block nonspecific binding sites.  For specific blocking, dilutions of 
purified unlabeled hybridoma immunoglobulin were added to the wells for  1 h  at 4°C.  The 
wells were again washed and  0.025  ml of 3H-labeled M2  protein  (25,000-50,000  cpm)  was 
added to each well for 1 h. After a  final wash in PBS-5, the wells were cut and transferred to 
scintillation fluid for counting. 
Antibody Absorption.  Cell suspensions for antibody absorptions were  prepared  by passing 
normal C57BL/6J  mouse tissues through a  wire mesh. Labeled monoclonal antibodies to be 
absorbed were either mixed vol:voi with packed cells, or with a  pellet containing a  known 
number of cells. After incubation for 1 h at 4°C, the cells were pelleted again for 6 min at 1,200 
rpm. The absorbed supernate was counted directly, or in some cases was tested for residual 
binding activity on T 15-coated microtiter wells. For antibody absorption with myelomas, T 15 
and normal mouse Ig coupled to Sepharose 4B were obtained from  R. Coffman.  0.1  ml of 
labeled antibody was mixed with 0.05 ml of packed Sepharose and incubated for 1 h at 4°C. 
The Sepharose was removed by pelleting at 1,200 rpm for 6 rain, and the supernate was tested 
for residual binding to the KKT-2 T  cell lymphoma. 
Results 
Isolation of the 42-21  Monoclonal Antibody.  Fisher rats were  immunized  against the 
spontaneous AKR T  lymphoma, KKT-2, to produce a series of monoclonal antibodies 
reactive with  normal  and  neoplastic lymphocytes. From  the original hybridization, 
100 wells were obtained that produced supernatant  fluids reactive with KKT-2 cells. 
Further  screening against  purified  KKT-2  SL  virus  resulted  in  50  of these,  which 
were found to react with viral structural proteins; these were excluded from this study. 
All but  two  of the remaining hybrids were  found to react with  normal T  cells and 
thymocytes, and thus were candidates for further screening against a panel of purified 
mouse myeloma proteins representing all immunoglobulin isotypes. 
In the initial screening, only three hybridoma supernatant  fluids bound to any of 
the myeloma proteins, and all of these showed the same pattern of reactivity: binding 
to the TI5 myeloma (a, i¢, PC binding), but to no other myeloma in the panel. Of the 
three T15-binding hybrids, two were lost before subsequent testing was possible. The 
remaining hybrid, 42-21, was grown to larger volume in flasks and then subcloned by 
limiting dilution on a  thymocyte feeder layer. Of the  15 subclones of 42-21, only one 
bound  to  KKT-2  cells;  this  same  clone was  also  the  only one  to  bind  to  the  T15 
myeloma protein. 
Characterization of the 42-21 Antigen on the T15 Myeloma.  Preliminary evidence on the 
nature of the 42-21  antigen was obtained by examining the binding of this antibody 
to a complete panel of purified myeloma proteins (Table I). Binding was observed for ERIC  PILLEMER  AND  IRVING L.  WEISSMAN 
TABLE  I 
42-21 Binding to Purified Myelomas* 
Binding  cpm/well§  Myeloma  Isotype  specificity~: 
T15  IgAx  PC  1530 ± 50 
S107  IgAK  PC  1150 ± 50 
HOPC8  IgA~¢  PC  1190 ±  70 
MOPC511  IgAr  PC  160 ± 0 
McPC603  IgAr  PC  150 ± 20 
MOPC 167  IgAx  PC  170 ± 20 
W3207  IgAK  PC  150 ± 0 
W3129  IgAx  1,6D  150 ±  10 
MOPC315  IgA~  DNP  140 ± 0 
J558  lgA~  1,3D  130 ± 0 
MOPC21  IgGlx  --  150 + 0 
GPC7  IgG2A~  --  170 + 20 
MOPCI41  IgG~ng  --  100 + 20 
J606  IgG~  2,1F  150 + 0 
W3469  IgM~  --  144 ± 30 
* Myeloma  binding  was  determined  by  solid-phase  immunoassay  using 
[3H]leucine-labeled 42-21 antibody. 
~: DNP: 2,4-dinitrophenyl;  1,3D: a  (1 --~ 3) dextran; 1,6D:a(l  ---* 6) dextran; 
2,1F: fl-(2 --~ 1) fruetosan. 
§ Mean cpm bound/well + SD. 
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42-21 only in the case ofT15  and the very closely related proteins S107 and HOPC8. 
The  42-21  antibody  does  not  bind  to  other  myelomas,  including similar a,  x,  PC- 
binding proteins such as W3207 and MOPC603. This pattern of reactivity is consistent 
with  that  of an  anti-T15  idiotype, and  thus  the  determinant  recognized  by  42-21 
must lie within the T15 variable region. 
Using  a  panel  of  isolated  heavy  and  light  chains,  recombined  molecules  and 
hybridomas, the antigenic site on the T15  molecule was localized further  (Table II). 
The 42-21  antibody binds to isolated T15 light chains, but not to T15  heavy chains, 
and selectively interacts with recombined or hybridoma immunoglobulins containing 
the TI5  light chain.  In an  inhibition study, the M2  hybridoma  (T15  L, TI5  H,  as 
determined by amino acid sequence) was found to inhibit completely the binding of 
labeled M2  to 42-21,  whereas  the M3  hybridoma  (MOPC603  L, T15  H, by amino 
acid sequence) had no effect (Fig. 1). These findings are consistent with the conclusion 
that  42-21  detects a  T15-specific idiotype on  the V~ light chain.  The 42-21  antigen 
was not  detected on  normal immunoglobulin  from  unimmunized  BALB/c mice. In 
addition, this V, determinant is distinct from the x chain marker described by Claflin 
(12),  because the 42-21  hybridoma binds equally well to both  types of light chains 
(Table II). 
To  test  whether  the  42-21  antigen  is  binding-site related,  blocking studies  were 
performed with  the PC  hapten.  Antibody binding is only weakly inhibited by high 
concentrations of free hapten  (data not shown), but even trace amounts of a  PC-BSA 
conjugate  significantly block  42-21  binding  to  T15  (Fig.  2);  71-11,  a  monoclonal 
antibody that recognizes a cross-reactive idiotype present on all PC-binding myelomas, 1072  A  V~-TEPC15  IDIOTYPE  CROSS-REACTIVE  WITH  Thy-I 
TABLE  II 
42-21  Binding to Myelomas, Recombined Molecules, Hybridoma Immunoglobulins, and Isolated Heavy and 
Light  Chains* 
Ig source  Isotype  Vn  VL  cpm/well~: 
Myelomas 
T15  IgAx  T15  T15  1,530 ±  50 
McPC603  IgAx  McPC603  McPC603  150 +  20 
Recombined molecules 
T 15/McPC603  IgAx  McPC603  T 15  1,820 ±  70 
Normal BALB/c Ig  --  --  --  t28 ±  4 
Hybridomas 
M2  IgMK  T15  T15  1,301 ±  28 
M3  IgM~¢  TI5  McPC603  85 ±  10 
GI  IgG~r  T15  MOPCI67  107 4-  14 
(V~c-Pc  a) 
221A4  IgM~c  TI5  TI5  1,083 4- 8 
(V~-Pc') 
991G2  IgMK  T15  Tiff  1,213 ±  31 
fv~-Pc~ 
552D3  IgMx  T15  T15  1,085 +  100 
Isolated chains 
T15 H  IgA-  T15  --  206 ±  1 
T15 L  -~  --  TI5  832 ±  10 
W3207L  -x  --  W3207  155 ±  12 
* Myeloma binding was determined by solid-phase immunoassay using [ZH]leucine-labeled 42-21 antibody. 
~: Mean cpm bound/well +  SD. 
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Fro.  1.  Inhibition of 3H-labeled M2 binding to 42-21  antibody. 42-21  antibody was immobilized 
in microtiter wells using a rabbit anti-rat Ig first stage. Various dilutions of unlabeled M2 O'15 H, 
T15 L) or M3 0"15 H, McPC603 L) hybridoma immunoglobulins were used to block the binding 
of 3H-labeled M2 protein to the plate-bound 42-21. 
is not  blocked  by PC-BSA.  This  implies  that  the antigen  recognized  by 42-21  is close 
to the  PC  binding  site ofT15. 
Characterization  of the 42-21  Antigen on  T  Lymphocytes.  After  the  characterization  of ERIC  PILLEMER  AND  IRVING  L.  WEISSMAN 
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Flo.  2.  Hapten  inhibition  of 42-21  antibody  binding to  TI5.  Various  dilutions of a  PC-BSA 
conjugate were preincubated in Tl5-coated microtiter wells to inhibit the binding of synthetically 
labeled antibody. 71-11 is a  hybridoma that recognizes a  cross-reactive idiotype present on all PC- 
binding myelomas. 
TABLE  III 
42-21 Binding to Lymphomas and Normal Lymphoid Tissue* 
Cell source  Cell type 
Antibody 
42-21  31-11 
Percent posi-  Median fluo-  Percent posi-  Median fluo- 
tive  rescence:~  tive  rescence 
Normal tissue~ 
Tumor cells 
Thymus  95.6  23  94.3  100 
Lymph node  61.1  27  64.9  100 
Spleen  20.5  16  22.1  100 
Bone marrow  4.2  9  4.5  7 
KKT2  --  24  --  75 
VL-3  --  30  --  100 
EL-4  --  49  --  100 
L691  --  35  --  100 
P815  --  0  --  0 
NS-1  --  0  --  1 
L1-2  --  0  --  0 
RAWll2  --  0  --  0 
* Suspensions of the various ceils were incubated with the indicated antibody, followed by a  FITC-labeled 
rabbit anti-rat Ig second stage. Analysis was performed on a  FACS. 
:1: Relative fluorescence standardized to a  scale with 31-11  staining on thymocytes arbitrarily  assigned a 
value of 100. 
§ Cell suspensions were prepared from normal lymphoid tissues of 6-wk-old male C  ×  B/J mice. 
the  42-21  antigen  on  T15  as a  V~ idiotype,  the  antibody  was  investigated  for binding 
to  a  panel  of  normal  lymphoid  cells  and  tumors  (Table  III).  The  42-21  antibody 
binds  to  all  T  cell  tumors,  but  not  to  non-T  tumors,  and  shows  a  pattern  of binding 1074  A V,-TEPCI5 IDIOTYPE CROSS-REACTIVE WITH Thy-1 
to normal lymphoid cells identical to that of an anti-Thy-1 hybridoma, 31-11  (16). 
The reduced median  fluorescence on T  cells observed with  42-21  when  compared 
with 31-11 is probably related to differences in the ability of the FITC-labeled second 
stage to react with different rat isotypes (IgM vs. IgG). In addition, staining of frozen 
lymphoid sections is confined to T-dependent areas  (R.  Rouse, personal communi- 
cation). By absorption, the 42-21 antigen is found on all lymphoid tissues, but not on 
other organs, such as liver (Fig. 3). Brain tissue was almost as effective as thymus in 
absorbing out the 42-21 antibody. 
Because the Thy- 1 antigen is found also on the brain and thymus, well-characterized 
anti-Thy- 1 antibodies were examined for their ability to block the binding of 42-21 to 
thymocytes (Fig. 4). The anti-Thy- 1 monoclonal, 31-11, blocks 42-21 binding, whereas 
other monoclonals specific for Lyt-1, Lyt-2, or a  cross-reactive PC  idiotype (71-11) 
have no effect. The relationship between the Thy-1 molecule and the 42-21  antigen 
is supported by several additional independent lines of evidence: (a) the failure of the 
42-21 antibody to bind to Thy-1- mutant cell lines (Fig. 5); (b) the localization of 42- 
21  and  anti-Thy-1  antibodies  to  the  same  cells  in  the  brain,  as  determined  by 
immunohistochemical analysis on  frozen sections  (R.  Rouse, personal communica- 
tion);  and  (c)  the  precipitation  of a  25,000-28,000  mol  wt  glycoprotein from  the 
surface  of labeled  T  lymphomas  and  lymphocytes  (9).  Thus,  the  42-21  antibody 
appears to recognize the Thy-1 antigen on all T  lymphocytes. 
Demonstration of the Cross-Reaction between TI5 and  Thy-1.  Although the 42-21  cell 
line has been subcloned by limiting dilution, the binding of this antibody to both the 
T15  myeloma protein  and  the  Thy-1  molecule theoretically could  be  due  to  two 
antibody populations  present  in  the  same  hybridoma supernate.  To rule out  this 
possibility, it was necessary to investigate the ability of one of these antigens to absorb 
out  antibody activity against  the other antigen.  Absorption of the 42-21  antibody 
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Fro. 3.  Absorption  of  42-21 antibody with mouse  tissues. 3H-labeled  42-21 antibody was incubated 
vol:vol with cell suspensions of various mouse tissues. After centrifugation,  residual antibody in the 
supernate was determined by scintillation counting. ERIC  PILLEMER AND IRVING L.  WEISSMAN  1075 
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Fio.  4.  Croes-blocking of 42-21  binding  to  thymocytes  with  defined  monoclonaJ  antibodies. 
Thymus cells were preincubated with unlabeled blocking antibodies,  and then  tested  in  a  cell 
binding assay using °H-labeled 42-21 antibody. 
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Fzo. 5.  Binding of 42-21 antibody to Thy-l mutants.  42-21 antibody binding was tested in a two- 
stage  cell-binding  assay  using  a  125I-labeled rabbit  anti-rat  Ig second  stage.  BW5147.3 and 
BW5147.6.1 are Thy-1- mutants of the Thy-I  + parent BW5147. 
with  thymocytes  removes  all  activity  against  the  T15  myeloma,  whereas  similar 
absorption of another monoelonal antibody recognizing a  cross-reactive PC idiotype 
not  present on  T  cells (71-11)  has  no  effect  (Fig. 6).  Similarly, absorption of 42-21 
with  T15-Sepharose  removes  binding  to  thymocytes,  whereas  normal  mouse  Ig- 
Sepharose has no effect (Fig. 7). Thus,  it is evident that the binding of 42-21  to both 1076  A  V,,-TEPC15  IDIOTYPE  CROSS-REACTIVE WITH  Thy-1 
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Fro.  6.  Absorption of 42-21 antibody with thymocytes, all-labeled antibody was absorbed with 
various numbers ofC × B/J normal thymocytes  and then tested for residual binding activity against 
TI5 in a solid-phase immunoassay. 71-11 is a hybridoma that recognizes a cross-reactive  idiotype 
present on all PC-binding myelomas. 
Fro.  7.  Absorption of  42-21 antibody with T 15. SH-labeled 42-21 was absorbed with T 15-Sepharose 
or normal mouse Ig-Sepharose,  and then tested for residual  binding activity against the KKT-2 T 
lymphoma in a ceil-binding assay. ERIC  PILLEMER  AND  IRVING  L.  WEISSMAN  1077 
Thy- 1 and T15 represents a true cross-reaction, rather than a contaminating antibody 
specificity present in the hybridoma supernate. 
Discussion 
In an attempt to identify cell surface molecules on T  lymphocytes that cross-react 
with  immunoglobulin,  we  have  isolated  a  monoclonal  antibody  that  detects  an 
antigenic determinant shared by V,-T15 and the Thy-1 molecule. This unexpected 
cross-reaction is of  interest because it conclusively demonstrates that a unique idiotypic 
determinant  present  on  a  purified  immunoglobulin is  shared  by another  normal 
cellular component present on all T cells. This finding may represent merely a trivial 
cross-reaction of no structural or functional significance, or it may imply a role for the 
Thy-1 molecule in antigen and/or mitogen recognition. The Thy-1 molecule has been 
shown to possess structural homology to an immunoglobulin domain (17), and highly 
significant sequence homology to VH and VL regions (A. Williams and J. Gagnon, 
personal communication). In addition, it has been suggested that the Thy-1 antigen 
plays a  functional role in morphogenetic changes in cultured epithelial cells (18),  in 
recirculation of mature T  cells (19), and in the in vitro development of myogenic cell 
lines (20). 
It is interesting to note our own experiments using the 42-21  antibody to block 
normal and neoplastic T  cell growth and function. We have shown that the 42-21 
antibody significantly inhibits T  cell-mediated allogeneic killing (N.  Hollander, E. 
Pillemer, and  I.  L.  Weissman,  manuscript  in  preparation)  and  also  inhibits virus 
binding  to  virus  receptors  on  T  lymphoma cells  (9).  Both  of these  phenomena 
probably represent steric hindrance of antigen or viral receptors, but it is possible that 
the Thy-1 molecule itself could be linked to T  cell receptors as part of a  mitogenic 
apparatus.  In  addition,  we  have  demonstrated  that  anti-Thy-1  antibodies  block 
concanavalin A-induced T  cell mitogenesis (21) and T  lymphoma cell proliferation 
(9,  16) in vitro. This provides further support for a direct role for the Thy-1 molecule 
in normal and neoplastic T  cell growth control. 
The occurrence of the Thy- 1 antigen on both T cells and cells of the central nervous 
system is  a  particulady intriguing phenomenon.  Although the Thy-1  molecule is 
found on many different cell types in the brain  (22),  it has been suggested that it 
plays a selective role in synaptic transmission. Thus, injection of anti-Thy-1 antibodies 
into a  rat  hypothalamus results in selective blockade of cholinergic function  (23). 
Recently, Fuchs et al. (24) have detected a thymic cell surface antigen using antibodies 
prepared against purified acetylcholine receptors. Although highly speculative, it is 
interesting to consider the relationship of these observations to our finding of a cross- 
reactive idiotype on the Thy-1 molecule and the T 15 myeloma, a molecule that binds 
acetylcholine as well as PC (25). 
As our studies on the 42-21  antigen have demonstrated, serological identity cannot 
be equated with structural or functional similarity. A similar unexpected crossreactiv- 
ity between light chains and T  cells was found to be due to a  determinant on fl-2 
microglobulin (26). Attempts to isolate and characterize the T cell receptor for antigen 
will continue to rely heavily on detection of immunoglobulin-related molecules on T 
cells,  using  antisera  prepared  against  purified  immunoglobulin.  However,  future 
studies on the T cell receptor must take into account the possibility that such antisera 1078  A V,-TEPC15 IDIOTYPE CROSS-REACTIVE WITH Thy-1 
(or even monoclonal antibodies) may recognize a cell surface antigen on all or a subset 
of T  cells shared by a normal component unrelated to classical immunoglobulin. 
Summary 
To  identify T  lymphocyte antigens  with  immunoglobulin-like  determinants,  we 
prepared rat anti-mouse T  cell monoclonal antibodies and screened them against a 
panel of purified mouse myeloma proteins representing all isotypes of immunoglob- 
ulin.  One  hybridoma,  designated  42-21,  was  found  to  detect  a  novel  antigenic 
determinant  shared by V,-TEPC15  and the Thy-1 molecule on all T  lymphocytes. 
Although several explanations for this unusual phenomenon exist, it may imply some 
role  for the Thy-1  molecule in  antigen  and/or  mitogen  recognition.  In any event, 
future studies of idiotypes on T  lymphocytes must consider the possibility that anti- 
idiotypic sera detect cell surface molecules unrelated to classical immunoglobulin. 
Received  for publication 29 December 1980. 
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